CTLA4 and uveitis: Among the reported medications, anti‐CTLA4 (ipilimumab) had an ocular toxicity rate of 1.3%,7 including anterior uveitis, optical neuropathy, Grave's syndrome‐like oculopathy and Vogt‐Koyanagi‐Harada (VKH) like syndrome.8 Vemurafenib had an ocular side‐effect rate of 4%, which mostly comprised uveitis,8 while anti‐PD‐1 was reported to have side‐effects of blurred vision and tearing.1, 9